Diagnostic and Prognostic Value of Global Longitudinal Strain in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

1	Yujiao Shi ¹ , Wang Qing ¹ , Chunqiu Liu ¹ , Xiong Shuang ¹ , Chenguang Yang ¹ ,
2	Wenbo Qiao ¹ , Guoju Dong ^{1, 2*} Jiangang Liu ^{2*}
3	
4	¹ Department of Cardiovascular Internal Medicine, Xiyuan Hospital, Chinese Academy of
5	Traditional Chinese Medicine, Beijing, China
6	² National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital,
7	Chinese Academy of Traditional Chinese Medicine, Beijing, China
8	
9	* Corresponding Author
10 11	E-mail: Guoju Dong. e-mail: 13691393589@163.com (GD); liujiangang2002@sina.com (JL)
12 13 14 15 16 17 18 19 20 21 22 23	
24	

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

Abstract **Objective:** Heart failure with preserved ejection fraction (HFpEF), an increasing public health concern, is increasing in prevalence and is associated with an elevated risk of hospitalization and mortality. Currently, data on the clinical application value of left ventricular global longitudinal strain (LV GLS) in HFpEF are contradictory. Therefore, we performed the following meta-analysis to appraise the diagnostic and prognostic value of LV GLS in HFpEF. Methods: PubMed, Medline, Scopus, and Web of Science were retrieved exhaustively from their inception until December 20, 2022, to obtain literature assessing the diagnostic and prognostic value of LV GLS in HFpEF. **Results:** Forty-one studies (including 14,543 patients) published from 2008 to 2022 were included. The results of the meta-analysis were as follows: First, the LV GLS values in HFpEF patients were significantly lower than in healthy individuals (SMD:1.21; 95% CI (0.94, 1.47), p<0.00001, I²=85%; P<0.00001), but substantially higher than in HErEF patients (SMD: -2.03; 95% CI (-2.23, -1.72), p<0.00001, I²=92%; P<0.00001). Second, the pooled diagnostic parameters of LV GLS for HFpEF were as follows: sensitivity, 0.77 (95% CI: 0.71–0.82); specificity, 0.66 (95% CI: 0.58–0.74); DOR, 7.53 (95% CI: 3.19–17.74); AUC for the SROC, 0.81 (95% CI: 0.79–0.87). Finally, the low LV GLS values were correlated with a higher risk of all-cause death (HR: 1.12; 95% CI: 1.01-1.25; p=0.000, $I^2=84\%$; P = 0.031) in HFpEF patients. **Conclusions:** LV GLS is impaired in HFpEF patients despite a normal left ventricular ejection fraction, indicating the existence of mild LV contractile dysfunction. Moreover,

LV GLS might be an auxiliary indicator for diagnosing HFpEF and predicting all-cause

death in HFpEF patients. Keywords: Global longitudinal strain; Heart failure with preserved ejection fraction; Diagnosis; Prognosis; Meta-analysis

1 Introduction

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

Heart failure (HF) with preserved ejection fraction (HFpEF), a complex and heterogeneous ailment, is a multi-organ disorder caused by an aging populace and comorbidities such as obesity, hypertension, diabetes, and chronic renal insufficiency[1]. HFpEF, comprising approximately half of the population of HF, is increasing in prevalence and is associated with an elevated risk of hospitalization and mortality[2,3]. Nevertheless, the clinical manifestations of HFpEF are atypical, and the pathogenic mechanism remains poorly understood, limiting clinical diagnosis and therapeutic options[4,5]. Accordingly, early and accurate diagnosis of HFpEF and determination of prognosis can contribute to implementing appropriate interventions to slow or halt disease progression and improve long-term consequences. Despite the fact that patients with HFpEF have a left ventricular (LV) ejection fraction (LVEF) of greater than or equal to 50%, cardiac contractile performance may still be damaged, especially in individuals with severe concentric cardiac hypertrophy or a small LV cavity[6]. LVEF, a measure of overall cardiac systolic function derived from two-dimensional echocardiographic images, may be limited by altered cardiac geometry, boundary tracking difficulties, and other factors[7,8]. Compared with LVEF measurement, myocardial strain, which represents the percentage deformation of the myocardium in three directions (longitudinal, circumferential, and radial) during the cardiac cycle, is an emerging metric allowing more precise quantification of global and regional myocardial contractile function[9]. LV global longitudinal strain (LV GLS), which can be measured by speckle-tracking echocardiography (STE) or feature-tracking cardiovascular magnetic resonance (FT-CMR), is a commonly used myocardial strain parameter in cardiovascular diseases[10]. In recent years, multiple clinical trials have analyzed the diagnostic or prognostic significance of LV GLS in HFpEF, but they provided inconsistent results. In this situation, we implemented a meta-analysis to estimate the diagnostic and prognostic value of LV GLS in HFpEF.

2 Materials and methods

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

2.1 Literature Search Strategy

This systematic review and meta-analysis was performed depending on the principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 statement (PRISMA)[11]. Two investigators (Shi and Wang) systematically performed documentary searches in four electronic databases (PubMed, Medline, Scopus, and Web of Science). English-language literature published from the inception of each database until December 20, 2022, was searched. Terms related to "Heart Failure, Diastolic", "Heart Failure with Preserved Ejection Fraction", "Heart Failure with Normal Ejection Fraction", "Diastolic Dysfunction", "Preserved Ejection Fraction", "Global Longitudinal Strain", and "GLS" were utilized following the rules of each database. For PubMed, the following search was performed: (((((Heart Failure, Diastolic[MeSH Terms]) OR (Heart Failure with Preserved Ejection Fraction[Title/Abstract])) OR (Heart Failure with Normal Ejection Fraction[Title/Abstract])) OR (Diastolic Dysfunction[Title/Abstract])) OR (Preserved Ejection Fraction[Title/Abstract])) **AND** ((Global Longitudinal Strain[Title/Abstract]) OR (GLS[Title/Abstract]))

2.2 Literature Inclusion and Exclusion Criteria

The inclusion criteria for this study were as follows: (i) diagnostic criteria: Fulfilment of diagnostic criteria for HF, patients with HFpEF had an LVEF≥45%, while HFrEF patients had an LVEF ≤40%[12,13]; (ii) study design: observational studies like case-control studies, prospective and retrospective cohort studies; (ii) endpoints: difference in LV GLS values between HFpEF patients and control groups (health controls or HFrEF patients), as well as the connection between LV GLS and diagnosis or adverse endpoints of HFpEF. The exclusion criteria for this study were as follows: (i) irrelevant or duplicated studies; (ii) the papers were case reports, reviews, letters, commentaries, editorials, or non-human studies; and (iii) the articles lacked full text or sufficient crude data.

2.3 Literature Quality Evaluation and Data Extraction

The quality estimation of the enrolled studies was evaluated by two independent reviewers (Xiong and Liu) using the Newcastle–Ottawa Quality Assessment Scale (NOS) system, a "star-based" grading system comprised of three parts (selection, comparability, and outcomes). A total NOS score ranged from 0 to 9, and studies achieving a score of 6 or above were considered high quality (Supplementary Table 1).

The required data from the included research was extracted and tabulated in specifically constructed Microsoft Excel spreadsheets for analysis. The extracted contents were as follows: (i) publication details: last name of the first author, year of publication, and the country setting; (ii) demographic characteristics: sample size, proportions of males, and mean age; (iii) study details: study design, LV GLS measurement method, data available to calculate the standardized mean difference (SMD) of LV GLS values between HFpEF patients and control groups (sample size, mean of LV GLS values and

standard deviation), data related to diagnostic meta-analysis (LV GLS cut-off, area under the curve (AUC), sensitivity (SEN), specificity (SPE), true positive (TP), false positive (FP), false negative (FN), true negative (TN)), and data associated with prognostic meta-analysis (variables adjusted, follow-up duration, endpoints (HF hospitalization, cardiovascular (CV) hospitalization, CV death, and All-cause death), hazard ratios (HRs) and 95% confidence intervals (CIs)); and (iv) NOS quality scores. Two independent researchers (Yang and Qiao) conducted data extraction, and disagreements were resolved by mutual coordination or third-party adjudication (Dong and Liu).

2.4 Statistical Analysis

Meta-Disc (Version 14.0) was used to analyze the diagnostic value of LV GLS in HFpEF. The pooled SEN, SPE, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and AUC for the summary receiver operating characteristic curves (SROC) were used to characterize the diagnostic performance. Review Manager (Version 5.4) was used to analyze the difference in LV GLS values between HFpEF patients and control groups. SMD and 95% CIs expressed the pooled effect sizes. STATA (Version 16.0) was used to assess the association between LV GLS and adverse outcomes of HFpEF. HRs and 95% CIs represented the pooled effect sizes. The heterogeneity among the included studies was appraised by the Cochran Q statistics (chi-square test) and quantified with the 12 statistic. The fixed-effect model was employed when the Q test (I²≤50%, p>0.05) revealed no significant heterogeneity across studies. When the Q test (I²≥50% or p<0.05) found prominent heterogeneity among studies, the random-effect model was utilized, followed by a Galbraith plot to explore the source of heterogeneity. Publication bias was evaluated using Deeks' funnel plot, Funnel

plot, and Egger's test. Sensitivity analysis was employed to assess the impact of single research on the overall estimate by omitting one study each time. P<0.05 was considered to be statistically significant.

3 Results

3.1 Literature Search Results

A flowchart of the database search and text screening procedure is demonstrated in Fig 1. 2,492 publications were retrieved through database searching, consisting of 372 from PubMed, 624 from Medline, 559 from Scopus, and 937 from Web of Science. After excluding 874 duplicates, we screened the titles and abstracts of 1,618 papers. 1,524 articles were removed following the inclusion and exclusion criteria. Finally, among the remaining 94 studies, two independent researchers (Shi and Wang) read the full text and excluded 53 records due to repetitive research, irrelevant results, and insufficient data. Overall, 41 articles in total were enrolled in the meta-analysis.

3.2 Characteristics of Included Studies

Forty-one studies [14-53] published from 2008 to 2022 were investigated, including 27 case-control studies, 12 prospective cohort studies, and 2 retrospective cohort studies. Table 1 shows the baseline features of the selected research. A total of 14,543 patients (10,193 HFpEF patients, 6,931 males, mean age of 67.66 years) were involved. Thirty-two studies detected LV GLS using STE, and the other 9 utilizing FT-CMR. Thirty-eight studies reported mean LV GLS values in HFpEF patients (-8.2% - -20.8%), whereas the

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

remaining 3 informed the median values (-15.3% - -20%). Concerning endpoint events, 27 studies evaluated the differences in LV GLS values between HFpEF patients and healthy controls (21 research) or HFrEF patients (16 research), and 26 studies assessed the diagnostic (6 trials) and prognostic (18 trials) significance of LV GLS in HFpEF. The NOS scores of included research varied from 6 to 9, indicating that the methodological quality was generally reliable (S1 Appendix). 3.3 Differences in LV GLS Values Between HFpEF Patients and Control Groups Twenty-one studies[14–34] explored the differences in LV GLS values between HFpEF patients (n=1431) and healthy controls (n=864), with a mean LV GLS of -16.07%±3.32% vs. -19.54%± 2.57% (Fig 2A). Moreover, 16 studies[14–18,21,26,30,33– 40] examined discrepancies in LV GLS values between HFpEF patients (n=2,234) and HFrEF patients (n=3,355), with an average LV GLS of -16.42%±3.56% vs. -9.3%±3.48% (Fig 2B). Meta-analysis using a random-effect model revealed that the LV GLS values in HFpEF patients were significantly lower than in healthy individuals (SMD:1.21; 95% CI (0.94, 1.47), p<0.00001, I²=85%; P<0.00001) (Fig 2C), but substantially higher than in HErEF patients (SMD: -2.03; 95% CI (-2.23, -1.72), p<0.00001, I²=92%; P<0.00001) (Fig 2D). According to the Galbraith radial plots, the research by (Fang et al., Wang et al., Sanchis et al.) and (Maffeis et al., Carluccio et al., and Yip et al.) were sources of heterogeneity for the above two comparison groups, respectively (S2 Appendix. 1A, 2A). The associated Funnel plots were asymmetrical (S2 Appendix. 1B, 2B) and the p-values of Egger's test were 0.2 and 0.41 (S2 Appendix. 1C, 2C), indicating a potential publication bias among included studies. The sensitivity analyses removing one research each time indicated that none of the individual trials substantially impacted the pooled estimates (S2 Appendix. 1D, 2D). Overall, the results of this study were relatively constant.

3.4 Diagnostic Value of LVGLS in HFpEF

Six studies[20,23,27,31–33] estimated the diagnostic usefulness of LV GLS values in HFpEF compared with healthy controls, with LV GLS cut-off values ranging from -16% to -24.1 and AUC from 0.68 to 0.98 (Table 2). Five trails provided complete data for diagnostic meta-analysis (SEN, SPN, TP, FP, FN, and TN). The SROC curve revealed no typical "shoulder-arm" pattern, while the Spearman correlation coefficient between the logarithm of sensitivity and the logarithm of (1-specificity) was -0.1, P=0.873, suggesting no threshold effect in the meta-analysis. Summary assessments of the diagnostic performance of LV GLS in HFpEF were as follows: SEN was 0.77 (95% CI: 0.71–0.82) (Fig 3A); SPE was 0.66 (95% CI: 0.58–0.74) (Fig 3B); PLR was 2.17 (95% CI: 1.36–3.47) (Fig 3C); NLR was 0.35 (95% CI: 0.21–0.59) (Fig 3D); DOR was 7.53 (95% CI: 3.19–17.74) (Fig 3E); AUC for the SROC was 0.81 (95% CI: 0.79–0.87) (Fig 3F). The p-value of Deeks' test (0.18) was greater than 0.05, suggesting no significant publication bias. (S2 Appendix. 3).

3.5 Prognostic Value of LV GLS in HFpEF Patients

Eighteen studies[6,28,37,40–53] examined the connection between LV GLS values as a continuous variable and adverse outcomes in HFpEF patients. The duration of follow-up varied from 4 to 144 months. In 9 studies, variables such as age, sex, race, history of CV disease, medication history, laboratory tests, and others that might affect the

association between LV GLS and research outcomes were adjusted (Table 3). Metaanalyzes with random-effects models showed that the low LV GLS values in HFpEF patients were associated with a higher risk of all-cause death (HR: 1.12; 95% CI: 1.01-1.25; p=0.000, $I^2=84\%$; P=0.031)[29,42,44,47,49,51] (Fig 4A), but not with the composite outcomes (all-cause death and HF hospitalization (HR: 1.03; 95% CI: 0.95-1.11; p=0.000, $I^2 = 83\%$; P=0.51)[29,45-48,51,52] (Fig 4B) or CV death and HF hospitalization (HR: 1.04; 95% CI: 0.94-1.14; p=0.000, $I^2 = 81\%$; P=0.49)) [6,28,37,41,43] (Fig 4C)). Additionally, three studies by Xu et al., Freed et al., and Kosmala et al. reported no association between low LV GLS values in HFpEF patients and the composite outcome of all-cause death and CV hospitalization [40,50,53]. The result for all-cause death showed substantial heterogeneity. The Galbraith radial plot suggested that the studies by Romano2020 et al. and Buggey2017 et al. may be the source of heterogeneity (S2 Appendix. 4A). the associated Funnel plot was asymmetric (S2 Appendix. 4B) and the p-value of Egger's test was 0.67 (S2 Appendix. 4C), suggesting a possible publication bias across included studies. The sensitivity analysis indicated that none of the studies significantly affected the pooled estimates (S2) Appendix. 4D).

4 Discussion

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

Current European Society of Cardiology guidelines graded HF based on LVEF into reduced (LVEF≤40%), mildly reduced (LVEF 41-49%), and preserved (LVEF≥50%) three subtypes[13]. HFpEF, which accounts for about half of all HF, is evolving as an increasingly severe public health concern[2]. Presently, HFpEF is diagnosed depending

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

on representative symptoms and/or signs of HF (breathlessness, fatigue, edema, and others), an LVEF of more than 50%, objective evidence of cardiac structural or functional abnormalities, and a growing level of BNP or NT pro-BNP[5]. However, most sufferers lack specific clinical manifestations in the initial stages and are usually not detected until the impairment of cardiac structure and function develops [54]. It is essential to explore effective metrics for identifying high-risk individuals, early diagnosis, prognosis assessment, and treatment monitoring. During cardiac systole, the obliquely and oppositely oriented subendocardial and epicardial myofibers produce apical counter-clockwise torsion and basal clockwise torsion, causing the LV to shorten in the longitudinal and circumferential planes while thickening in the radial plane [55]. Cardiac strain assesses the change in length of the myocardium in three planes (longitudinal and circumferential (expressed by a negative value), radial (represented by a positive value) relative to the initial length during the cardiac cycle. It can be calculated using the following formula: strain (epsilon) = L-Lo/Lo (where Lo is the baseline length of the myocardium, and L is the length after deformation)[7]. LV GLS, a sensitive and objective diagnostic indicator in cardiac strain imaging, can detect LV mild contractile dysfunction before changes in LVEF[8]. It is currently used as an auxiliary parameter for diagnosis and prognostic assessment in cardio-oncology[56] and is being expanded to other fields such as cardiac cardiomyopathies[58], valvular heart diseases[59], amyloidosis[57], pulmonary hypertension[60], and HF[58]. Although numerous studies have confirmed the presence of abnormal LV GLS in HFpEF patients and the Heart Failure Association consensus has unanimously recommended impaired V GLS as an ancillary criterion for the diagnosis of

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

HFpEF[54], there is controversy about whether LV GLS has independent diagnostic and prognostic value for HFpEF. We consequently performed this meta-analysis to assess the diagnostic and prognostic value of LV GLS in HFpEF. The results of the current meta-analysis illustrated a significant link between LV GLS and the diagnosis and prognosis of HFpEF. First, the LV GLS values in HFpEF patients were significantly lower than in healthy individuals, but substantially higher than in HErEF patients, confirming the presence of mild LV systolic dysfunction in HFpEF patients. The longitudinal systolic function of LV is determined by the endocardium, which is highly susceptible to the detrimental impacts of ischemia or hypertrophy[61,62]. Multiple comorbidities in HFpEF patients may promote microvascular malfunction and muscle fibrosis[63], reducing LV longitudinal systolic function and ultimately leading to LV GLS impairment. Second, LV GLS has excellent auxiliary diagnostic value for HFpEF, with with an AUC of 0.81 (95% CI: 0.79–0.87). Finally, the low LV GLS values in HFpEF patients were correlated with a higher risk of all-cause death, indicating that LV GLS is a powerful independent predictor of all-cause mortality in HFpEF patients. This meta-analysis involved a relatively comprehensive literature search, and the included studies were of excellent quality according to the NOS score. Nonetheless, some limitations must be considered: First, the heterogeneity of the included studies was high, with probable causes including the detection method of LV GLS, the diagnostic criteria of HF, and the study design. Second, in the diagnostic meta-analysis, the diagnostic cutoff values of LV GLS were not consistent, which might be related to factors like the detection technique. Third, in the prognostic meta-analysis, the follow-up periods were inconsistent, and the number of studies in which effect sizes could be combined for the

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

same endpoint was low, limiting the ability to draw significant conclusions. As a result, our meta-analysis is exploratory, and further high-quality original research is needed to support the findings of this study. Conclusion 5 LV GLS is impaired in HFpEF patients despite a normal left ventricular ejection fraction, indicating the existence of mild LV contractile dysfunction. Moreover, LV GLS might be an auxiliary indicator for diagnosing HFpEF and predicting all-cause death in HFpEF patients. **Supporting information** 6 S1 Appendix. NOS score of the included studies (PDF) S2 Appendix. Heterogeneity, publication bias, and sensitivity analysis of relevant meta-analyses (PDF) S3 Appendix.PRISMA checklist (PDF) Acknowledgments 7 The authors would like to express their gratitude to Professor W. Szymański for his valuable help in the process of retrieving relevant literature.

319

320

321

322

323

324

326

327

328

329

331

332

333

334

335

336

339

Author Contributions 8 Conceptualization: Yujiao Shi, Guoju Dong, Jiangang Liu Data curation: Yujiao Shi, Wang Qing Formal analysis: Wang Qing, Chunqiu Liu, Xiong Shuang **Investigation:** Chenguang Yang, Wenbo Qiao Methodology: Yujiao Shi, Guoju Dong, Jiangang Liu Project administration: Wang Qing, Chunqiu Liu, Xiong Shuang 325 **Supervision:** Guoju Dong, Jiangang Liu Visualization: Yujiao Shi, Chunqiu Liu Writing – original draft: Guoju Dong, Jiangang Liu Writing – review & editing: Yujiao Shi, Guoju Dong, Jiangang Liu 330 9 Data availability statement All relevant data are within the paper. 10 **Funding** This study was supported by grants from the National Natural Science Foundation of China (8207153216) and the Major Innovation Project of the China Academy of Traditional Chinese Medicine (CI2021A00903). 337 338

Reference

- 1. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. *Nature Reviews Cardiology* (2020) 17:559–73. doi: 10.1038/s41569-020-0363-2
- 2. Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, Chirinos JA, Collins S, Deo RC, Gladwin MT, et al. Research Priorities for Heart Failure With Preserved Ejection Fraction. *Circulation* (2020) 141:1001–26. doi: 10.1161/circulationaha.119.041886
 - 3. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nature Reviews Cardiology* (2017) 14:591–602. doi: 10.1038/nrcardio.2017.65
 - 4. Omote K, Verbrugge FH, Borlaug BA. Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. *Annual Review of Medicine* (2022) 73:321–37. doi: 10.1146/annurev-med-042220-022745
 - 5. Nagueh SF. Heart Failure with Preserved Ejection Fraction: Insights into Diagnosis and Pathophysiology. *Cardiovascular Research* (2021) 117:999–1014. doi: 10.1093/cvr/cvaa228
 - 6. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. *Circulation* (2015) 132:402–14. doi: 10.1161/CIRCULATIONAHA.115.015884
 - 7. Potter E, Marwick TH. Assessment of Left Ventricular Function by Echocardiography. *JACC: Cardiovascular Imaging* (2018) 11:260–74. doi: 10.1016/j.jcmg.2017.11.017
 - 8. Nauta JF, Jin X, Hummel YM, Voors AA. Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal. *European Journal of Heart Failure* (2018) 20:1636–8. doi: 10.1002/ejhf.1326
 - 9. Halliday BP, Senior R, Pennell DJ. Assessing left ventricular systolic function: from ejection fraction to strain analysis. *European Heart Journal* (2021) 42:789–97. doi: 10.1093/eurheartj/ ehaa587
 - 10. Amzulescu MS, De Craene M, Langet H, Pasquet A, Vancraeynest D, Pouleur AC, Vanoverschelde JL, Gerber BL. Myocardial strain imaging: review of general principles, validation, and sources of discrepancies. *European Heart Journal Cardiovascular Imaging* (2019) 20:605–19. doi: 10.1093/ehjci/jez041
 - 11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an Updated Guideline for Reporting Systematic Reviews. *British Medical Journal* (2021) 372:n71. doi: 10.1136/bmj.n71
- 12. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *New England Journal of Medicine* (2019) 381:1609–20. doi: 10.1056/nejmoa1908655
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. *European Heart Journal* (2021) 42:3599–726. doi: 10.1093/eurheartj/ehab368

14. Bekfani T, Hamadanchi A, Ijuin S, Bekhite M, Nisser J, Derlien S, Westphal J, Bogoviku J, Morris DA, Fudim M, et al. Relation of left atrial function with exercise capacity and muscle endurance in patients with heart failure. *ESC Heart Failure* (2021) 8:4528–38. doi: 10.1002/ehf2.13656

- 15. Blum M, Hashemi D, Motzkus LA, Neye M, Dordevic A, Zieschang V, Zamani SM, Lapinskas T, Runte K, Kelm M, et al. Variability of Myocardial Strain During Isometric Exercise in Subjects With and Without Heart Failure. *Frontiers in Cardiovascular Medicine* (2020) 7:111. doi: 10.3389/fcvm.2020.00111
- 16. Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D, Jaufeerally F, Leong KTG, Ong HY, Ng TP, et al. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. *European Journal of Heart Failure* (2017) 19:1664–71. doi: 10.1002/ejhf.873
- 17. Bshiebish HAH, Al-Musawi AH, Khudeir SA. Role of global longitudinal strain in assessment of left ventricular systolic function in patients with heart failure with preserved ejection fraction. *Journal of the Saudi Heart Association* (2019) 31:100–5. doi: 10.1016/j.jsha.2018.12.002
- 18. Carluccio E, Biagioli P, Alunni G, Murrone A, Leonelli V, Pantano P, Biscottini E, Paulus WJ, Ambrosio G. Advantages of deformation indices over systolic velocities in assessment of longitudinal systolic function in patients with heart failure and normal ejection fraction. *European Journal of Heart Failure* (2011) 13:292-02. doi: 10.1093/eurjhf/hfq203
- 19. Carluccio E, Biagioli P, Zuchi C, Bardelli G, Murrone A, Lauciello R, D'Addario S, Mengoni A, Alunni G, Ambrosio G. Fibrosis assessment by integrated backscatter and its relationship with longitudinal deformation and diastolic function in heart failure with preserved ejection fraction. *The International Journal of Cardiovascular Imaging* (2016) 32:1071–80. doi: 10.1007/s10554-016-0881-5
- 20. Fang S, Zhang Z, Wang Y, Jiang F, Yang K, He F, Zhang C. Predictive value of left ventricular myocardial strain by four-dimensional speckle tracking echocardiography combined with red cell distribution width in heart failure with preserved ejection fraction. *Echocardiography* (2019) 36:1074–83. doi: 10.1111/echo.14373
- 21. Hashemi D, Motzkus L, Blum M, Kraft R, Tanacli R, Tahirovic E, Doeblin P, Zieschang V, Zamani SM, Kelm M, et al. Myocardial deformation assessed among heart failure entities by cardiovascular magnetic resonance imaging. *ESC Heart Failure* (2021) 8:890–7. doi: 10.1002/ehf2.13193
- 22. Ito H, Ishida M, Makino W, Goto Y, Ichikawa Y, Kitagawa K, Omori T, Dohi K, Ito M, Sakuma H. Cardiovascular magnetic resonance feature tracking for characterization of patients with heart failure with preserved ejection fraction: correlation of global longitudinal strain with invasive diastolic functional indices. *Journal of Cardiovascular Magnetic Resonance* (2020) 22:42. doi: 10.1186/s12968-020-00636-w
- 428 23. Kim HY, Park S-J, Lee S-C, Chang SY, Kim E-K, Chang S-A, Choi J-O, Park SW, Kim S-M, Choe YH, et al. Comparison of global and regional myocardial strains in patients with heart failure with a preserved ejection fraction vs hypertension vs age-matched control. *Cardiovascular Ultrasound* (2020) 18:44.

432 doi: 10.1186/s12947-020-00223-0

- 24. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, et al. Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology (2014)63:447–56. doi: 10.1016/j.jacc.2013.09.052
 - 25. Löffler AI, Pan JA, Balfour PC, Shaw PW, Yang Y, Nasir M, Auger DA, Epstein FH, Kramer CM, Gan L-M, et al. Frequency of Coronary Microvascular Dysfunction and Diffuse Myocardial Fibrosis (Measured by Cardiovascular Magnetic Resonance) in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. *The American Journal of Cardiology* (2019) 124:1584–9. doi: 10.1016/j.amjcard.2019.08.011
 - 26. Luo X-X, Fang F, Lee AP-W, Sun J-P, Li S, Zhang Z-H, Sanderson JE, Kwong JSW, Zhang Q, Wang J, et al. What can three-dimensional speckle-tracking echocardiography contribute to evaluate global left ventricular systolic performance in patients with heart failure? *International Journal of Cardiology* (2014) 172:132–7. doi: 10.1016/j.ijcard.2013.12.314
 - 27. Mordi IR, Singh S, Rudd A, Srinivasan J, Frenneaux M, Tzemos N, Dawson DK. Comprehensive Echocardiographic and Cardiac Magnetic Resonance Evaluation Differentiates Among Heart Failure With Preserved Ejection Fraction Patients, Hypertensive Patients, and Healthy Control Subjects. *JACC: Cardiovascular Imaging* (2018) 11:577–85. doi: 10.1016/j.jcmg.2017.05.022
 - 28. Pellicori P, Kallvikbacka-Bennett A, Khaleva O, Carubelli V, Costanzo P, Castiello T, Wong K, Zhang J, Cleland JGF, Clark AL. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? *The International Journal of Cardiovascular Imaging* (2013) 30:69–79. doi: 10.1007/s10554-013-0310-y
 - 29. Roy C, Lejeune S, Slimani A, Meester C, Ahn AS SA, Rousseau MF, Mihaela A, Ginion A, Ferracin B, Pasquet A, et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. *ESC Heart Failure* (2020) 7:2494–507. doi: 10.1002/ehf2.12816
 - 30. Sanchis L, Gabrielli L, Andrea R, Falces C, Duchateau N, Perez-Villa F, Bijnens B, Sitges M. Left atrial dysfunction relates to symptom onset in patients with heart failure and preserved left ventricular ejection fraction. *European Heart Journal Cardiovascular Imaging* (2015) 16:62–7. doi: 10.1093/ehjci/jeu165
 - 31. Stoichescu-Hogea G, Buleu FN, Christodorescu R, Sosdean R, Tudor A, Ember A, Brie DM, Drăgan S. Contribution of Global and Regional Longitudinal Strain for Clinical Assessment of HFpEF in Coronary and Hypertensive Patients. *Medicina* (2021) 57:1372. doi: 10.3390/medicina57121372
 - 32. Tanacli R, Hashemi D, Neye M, Motzkus LA, Blum M, Tahirovic E, Dordevic A, Kraft R, Zamani SM, Pieske B, et al. Multilayer myocardial strain improves the diagnosis of heart failure with preserved ejection fraction. *ESC Heart Failure* (2020) 7:3240–5. doi: 10.1002/ehf2.12826
- 475 33. Wang J, Khoury DS, Yue Y, Torre-Amione G, Nagueh SF. Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. *European Heart*

Journal (2008) 29:1283–9. doi: 10.1093/eurheartj/ehn141

- 34. Yip GW-K ., Zhang Q, Xie J-M ., Liang Y-J ., Liu Y-M ., Yan B, Lam Y-Y ., Yu C-M . Resting global and regional left ventricular contractility in patients with heart failure and normal ejection fraction: insights from speckle-tracking echocardiography. *Heart* (2011) 97:287–94. doi: 10.1136/hrt.2010.205815
 - 35. Maffeis C, Rossi A, Cannata L, Zocco C, Belyavskiy E, Radhakrishnan AK, Feuerstein A, Morris DA, Pieske-Kraigher E, Pieske B, et al. Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction. *ESC Heart Failure* (2022) 9:842–52. doi: 10.1002/ehf2.13788
 - 36. Michalski B, Trzciński P, Kupczyńska K, Miśkowiec D, Pęczek Ł, Nawrot B, Lipiec P, Kasprzak JD. The differences in the relationship between diastolic dysfunction, selected biomarkers and collagen turn-over in heart failure patients with preserved and reduced ejection fraction. *Cardiology Journal* (2017) 24:35–42. doi: 10.5603/cj.a2016.0098
 - 37. Obokata M, Takeuchi M, Negishi K, Ohte N, Izumo M, Yamashita E, Ebato M, Yuda S, Kurabayashi M, Nakatani S. Relation Between Echocardiogram-Based Cardiac Parameters and Outcome in Heart Failure With Preserved and Reduced Ejection Fraction. *The American Journal of Cardiology* (2016) 118:1356–62. doi: 10.1016/j.amjcard.2016.07.060
 - 38. Park JJ, Park J-B, Park J-H, Cho G-Y. Global Longitudinal Strain to Predict Mortality in Patients With Acute Heart Failure. *Journal of the American College of Cardiology* (2018) 71:1947–57. doi: 10.1016/j.jacc.2018.02.064
 - 39. Tanacli R, Hashemi D, Lapinskas T, Edelmann F, Gebker R, Pedrizzetti G, Schuster A, Nagel E, Pieske B, Düngen H-D, et al. Range Variability in CMR Feature Tracking Multilayer Strain across Different Stages of Heart Failure. *Scientific Reports* (2019) 9:16478. doi: 10.1038/s41598-019-52683-8
 - 40. Xu L, Pagano J, Chow K, Oudit GY, Haykowsky MJ, Mikami Y, Howarth AG, White JA, Howlett JG, Dyck JRB, et al. Cardiac remodelling predicts outcome in patients with chronic heart failure. *ESC Heart Failure* (2021) 8:5352–62. doi: 10.1002/ehf2.13626
 - 41. Gozdzik A, Marwick TH, Przewlocka-Kosmala M, Jankowska EA, Ponikowski P, Kosmala W. Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction. *ESC Heart Failure* (2021) 8:1531–40. doi: 10.1002/ehf2.13247
 - 42. Kalra R, Gupta K, Sheets R, Aryal S, Ebrahimi A, Rajapreyar I, Cribbs MG, Booker OJ, Prabhu SD, Bajaj NS. Cardiac Function and Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). *The American Journal of Cardiology* (2020) 129:46–52. doi: 10.1016/j.amjcard.2020.04.038
 - 43. 43. Kammerlander AA, Donà C, Nitsche C, Koschutnik M, Schönbauer R, Duca F, Zotter-Tufaro C, Binder C, Aschauer S, Beitzke D, et al. Feature Tracking of Global Longitudinal Strain by Using Cardiovascular MRI Improves Risk Stratification in Heart Failure with Preserved Ejection Fraction. *Radiology* (2020) 296:290–8. doi: 10.1148/radiol.2020200195
- 522 44. Romano S, Judd RM, Kim RJ, Heitner JF, Shah DJ, Shenoy C, Evans K, Romer B, Salazar P, Farzaneh-Far A. Feature-Tracking Global Longitudinal Strain

- Predicts Mortality in Patients With Preserved Ejection Fraction. *JACC:* Cardiovascular Imaging (2020) 13:940–7. doi: 10.1016/j.jcmg.2019.10.004
- 45. Hwang I-C, Cho G-Y, Choi H-M, Yoon YE, Park JJ, Park J-B, Park J-H, Lee S-P, Kim H-K, Kim Y-J. H2FPEF Score Reflects the Left Atrial Strain and Predicts Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. Failure 27:198-207. Journal of Cardiac (2021)doi: 10.1016/j.cardfail.2020.09.474

- 46. Donal E, Lund LH, Oger E, Bosseau C, Reynaud A, Hage C, Drouet E, Daubert J-Claude, Linde C. Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction. *European Heart Journal Cardiovascular Imaging* (2017) 18:629–35. doi: 10.1093/ehjci/jex005
- 47. Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, Schulte PJ, Velazquez EJ. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. *ESC Heart Failure* (2017) 4:432–9. doi: 10.1002/ehf2.12159
- 48. Wang J, Fang F, Wai-Kwok Yip G, Sanderson JE, Feng W, Xie J-M, Luo X-X, Lee AP-W, Lam Y-Y. Left ventricular long-axis performance during exercise is an important prognosticator in patients with heart failure and preserved ejection fraction. *International Journal of Cardiology* (2015) 178:131–5. doi: 10.1016/j.ijcard.2014.10.130
- 49. Huang W, Chai SC, Lee SGS, MacDonald MR, Leong KTG. Prognostic Factors After Index Hospitalization for Heart Failure With Preserved Ejection Fraction. *The American Journal of Cardiology* (2017) 119:2017–20. doi: 10.1016/j.amjcard.2017.03.032
- 50. Freed BH, Daruwalla V, Cheng JY, Aguilar FG, Beussink L, Choi A, Klein DA, Dixon D, Baldridge A, Rasmussen-Torvik LJ, et al. Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. *Circulation: Cardiovascular Imaging* (2016) 9:e003754. doi: 10.1161/circimaging.115.003754
- 51. Lejeune S, Roy C, Ciocea V, Slimani A, de Meester C, Amzulescu M, Pasquet A, Vancraeynest D, Beauloye C, Vanoverschelde J-L, et al. Right Ventricular Global Longitudinal Strain and Outcomes in Heart Failure with Preserved Ejection Fraction. *Journal of the American Society of Echocardiography* (2020) 33:973-984.e2. doi: 10.1016/j.echo.2020.02.016
- 52. Weerts J, Barandiarán Aizpurua A, Henkens MTHM, Lyon A, van Mourik MJW, van Gemert MRAA, Raafs A, Sanders-van Wijk S, Bayés-Genís A, Heymans SRB, et al. The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. *European Heart Journal Cardiovascular Imaging* (2021) 23:74–84. doi: 10.1093/ehjci/jeab222
- 53. Kosmala W, Przewlocka-Kosmala M, Rojek A, Mysiak A, Dabrowski A, Marwick TH. Association of Abnormal Left Ventricular Functional Reserve With Outcome in Heart Failure With Preserved Ejection Fraction. *JACC: Cardiovascular Imaging* (2018) 11:1737–46. doi: 10.1016/j.jcmg.2017.07.028
- 54. Pieske B, Tschöpe C, Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, et al. How to diagnose heart failure with preserved

- ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *European Journal of Heart Failure* (2020) 22:391– 412. doi: 10.1002/ejhf.1741
- 55. Buckberg G, Hoffman JIE, Mahajan A, Saleh S, Coghlan C. Cardiac Mechanics Revisited. Circulation (2008) 118:2571–87. doi: 10.1161/circulationaha.107.754424

- 56. Moslehi JJ, Witteles RM. Global Longitudinal Strain in Cardio-Oncology. Journal of the American College of Cardiology (2021) 77:402–4. doi: 10.1016/j.jacc.2020.12.014
 - 57. Sivapathan S, Geenty P, Deshmukh T, Boyd A, Richards D, Stewart G, Taylor MS, Kwok F, Thomas L. Alterations in multi-layer strain in AL amyloidosis. *Amyloid* (2022) 21:1–9. doi: 10.1080/13506129.2022.2026914
 - 58. Steen H, Giusca S, Montenbruck M, Patel AR, Pieske B, Florian A, Erley J, Kelle S, Korosoglou G. Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or cardiac amyloidosis. *Journal of Cardiovascular Magnetic Resonance* (2021) 23:45. doi: 10.1186/s12968-021-00711-w
 - 59. Hiemstra YL, Tomsic A, van Wijngaarden SE, Palmen M, Klautz RJM, Bax JJ, Delgado V, Ajmone Marsan N. Prognostic Value of Global Longitudinal Strain and Etiology After Surgery for Primary Mitral Regurgitation. *JACC: Cardiovascular Imaging* (2020) 13:577–85. doi: 10.1016/j.jcmg.2019.03.024
 - 60. Shehata ML, Harouni AA, Skrok J, Basha TA, Boyce D, Lechtzin N, Mathai SC, Girgis R, Osman NF, Lima JAC, et al. Regional and Global Biventricular Function in Pulmonary Arterial Hypertension: A Cardiac MR Imaging Study. *Radiology* (2013) 266:114–22. doi: 10.1148/radiol.12111599
 - 61. Fan L, Namani R, Choy JS, Kassab GS, Lee LC. Transmural Distribution of Coronary Perfusion and Myocardial Work Density Due to Alterations in Ventricular Loading, *Geometry and Contractility. Frontiers in Physiology* (2021) 12:744855. doi: 10.3389/fphys.2021.744855
 - 62. Xu L, Pagano JJ, Haykowksy MJ, Ezekowitz JA, Oudit GY, Mikami Y, Howarth A, White JA, Dyck JRB, Anderson T, et al. Layer-specific strain in patients with heart failure using cardiovascular magnetic resonance: not all layers are the same. *Journal of Cardiovascular Magnetic Resonance* (2020) 22:81. doi: 10.1186/s12968-020-00680-6
 - 63. Arnold JR, Kanagala P, Budgeon CA, Jerosch-Herold M, Gulsin GS, Singh A, Khan JN, Chan DCS, Squire IB, Ng LL, et al. Prevalence and Prognostic Significance of Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. *JACC: Cardiovascular Imaging* (2022) 5:S1936-878X(21)008937. doi: 10.1016/j.jcmg.2021.11.022

Tabel 1. Baseline characteristics of the 41 selected research

NO	Study	Country	Sample size , n	HFpEF patients,	Males , n	Age, mean (SD), years	Study design	LV GLS detection method	Mean or median values of LV GLS in HFpEF patients (%)	Endpoin t (s)	NOS quality score
1	Ito2020	Japan	36	18	10	63	Case-control	FT-CMR	-14.8±3.3	A	8
2	Mordi2018	Uk	90	62	34	69.3	Case-control	STE	-16.0±2.2	A, C	7
3	Stoichescu- Hogea2018	Romania	102	62	53	61.5	Case-control	STE	-17.6±2.3	A, C	8
4	Carluccio2016	Italy	86	46	38	70	Case-control	STE	-15.4±3.5	A	8
5	Löffler2019	US	34	19	17	61	Case-control	FT-CMR	-17.9±3.5	A	7
6	Maffeis2022	Germany	171	86	136	65	Case-control	STE	-19.0 ± 3.0	В	6
7	Hashemi2021	Germany	49	19	35	66.9	Case-control	FT-CMR	-19.2±1.3	A, B	8
8	Bekfani2021	US	55	17	30	68.3	Case-control	STE	-18.9 ± 5.5	A, B	7
9	Blum2020	Germany	54	17	34	68.3	Case-control	FT-CMR	-19.1±1.2	A, B	8
10	Park2018	South Korea	3530	1335	1848	70.8	Case-control	STE	-15.2±4.6	В	9
11	Sanchis2015	Spain	138	63	90	75	Case-control	STE	-16.0 + 3.7	A, B	7
12	Bosch2017	Netherland s	657	219	328	66	Case-control	STE	-14.5±4.0	A, B	7
13	Bshiebish2019	Iraq	66	20	38	59	Case-control	STE	-15.0±2.0	A, B	8
14	Michalski2017	Poland	62	32	32	62.3	Case-control	STE	-16.1±6.4	В	8
15	Luo2014	China	149	45	93	61	Case-control	STE	-14.0±2.7	A, B	7
16	Fang2019	China	112	62	61	67.5	Case-control	STE	-14.5±2.6	A, C	7
17	Tanacli2020	Germany	40	20	24	70.8	Case-control	FT-CMR	-20.8±4.0	A, C	8
18	Kim2020	South Korea	96	50	42	62.8	Case-control	STE	-15.5±5.3	A, C	8
19	Kraigher- Krainer2014	Austria	269	219	140	70	Case-control	STE	-14.6 ±3.3	A	7
20	Tanacli2019	Germany	55	18	30	66.7	Case-control	FT-CMR	-12.2 ± 2.1	В	7
21	Yip2011	China	347	112	158	64.7	Case-control	STE	-15.9 ± 3.9	A, B	8
22	Wang2008	US	67	20	42	52.3	Case-control	STE	-13.0 ± 6.0	A, B, C	7
23	Carluccio2011	Netherland s	137	47	78	62.7	Case-control	STE	-14.4±3.3	A, B	7
24	Pellicori2014	UK	158	138	96	71.5	Case-control	STE	-13.6±3.0	A, D	6

619 Continued Tabel 1. Baseline characteristics of the 41 selected research

NO	Study	Country	Sample size , n	HFpEF patients, n	Males , n	Age, mean (SD), years	Study design	LV GLS detection method	Mean or median values of LV GLS in HFpEF patients (%)	Endpoin t(s)	NOS quality score
25	Xu2021	Canada	262	97	100	69	Case-control	FT-CMR:	-18.0 ±3.0	B, D	8
26	Roy2020	Brussels	174	143	56	73	Case-control	STE	-16.5±3.2	A, D	7
27	Obokata2016	Japan	442	102	265	74	Case-control	STE	14.3±2.8	B, D	6
28	Gozdzik2021	Australia	201	201	53	64.8	Prospective cohort	STE	18.3 ± 3.2	D	7
29	Kalra2020	US	1767	1767	885	72	Retrospective cohort	STE	-15.6	D	8
30	Kammerlander2020	Austria	206	206	63	71	Prospective cohort	FT-CMR	-8.2±4.5	D	8
31	Romano2020	US	1274	1274	681	57.1	Retrospective cohort	FT-CMR	-20	D	8
32	Hwang2021	South Korea	1105	1105	435	77	Prospective cohort	STE	-15.3	D	9
33	Donal2017	France	237	237	102	76	Prospective cohort	STE	-14.9±3.71	D	7
34	Buggey2017	US	739	739	177	69	Prospective cohort	STE	-13.4±3.8	D	8
35	Wang2015	China	80	80	50	66	Prospective cohort	STE	-18.15±3.3	D	8
36	Huang2017	Singapore	129	129	67	75.1	Prospective cohort	STE	-13.5±4.0	D	7
37	Shah2015	US	447	447	207	70.3	Prospective cohort	STE	-15.6±3.5	D	9
38	Freed2016	Chicago	308	308	111	65	Prospective cohort	STE	-17.5±4.1	D	8
39	Lejeune2020	Belgium	149	149	58	78	Prospective cohort	STE	-16.7±3.1	D	7
40	Weerts2021	Spain	258	258	79	75.6	Prospective cohort	STE	-17.7±4.4	D	6
41	Kosmala2018	Australia	205	205	55	64.8	Prospective cohort	STE	-18.2±3.4	D	8

Abbreviations: HFpEF: Heart (HF) with preserved ejection fraction; STE: speckle-tracking echocardiography; FT-CMR: feature-tracking cardiovascular magnetic resonance

Endpoint (s): A: Differences in LV GLS Values between HFpEF Patients and Healthy Controls; B: Differences in LV GLS Values between HFpEF Patients and HFrEF Patients; C: Diagnostic Value of LV GLS Values in HFpEF; D: Prognostic Value of LV GLS Values in HFpEF Patients

Table 2. Data related to diagnostic meta-analysis

	Study	LVGLS cut-off (%)	AUC	SEN (%)	SPE(%)	TP	FP	FN	TN	P-value
1	Mordi2018	-17.8	0.78	0.83	0.63	52	10	11	17	0.037
2	Stoichescu-Hogea2018	-19.35	0.83	0.79	0.47	49	21	13	19	< 0.001
3	Fang2019	_	0.87	_	_	_	_	_	_	< 0.001
4	Tanacli2020	-24.1	0.69	0.90	0.41	18	12	2	8	0.037
5	Kim2020	-16.7	0.68	0.54	0.85	27	7	23	39	0.001
6	Wang2008	-16	0.98	0.95	0.95	19	1	1	16	< 0.001

Abbreviations: LV GLS: left ventricular global longitudinal strain TP: True positive; FP: False positive; FN: False negative; TN: True negative; SEN: Sensitivity; SPE: Specificity.

Table 3. Data related to Meta-analysis of prognostic assessment

NO	Study	Variables adjusted	Follow-up Duration (months)	Endpoint(s)	Hazard ratios	95%CIs	P- value
1	Pellicori2014	-	21.6	CV death and HF hospitalization	1.09	1.00-1.19	0.046
2	Xu2021	_	90	All-cause death and CV hospitalization	1.00	0.98-1.02	0.93
		-		All cause death	1.04	0.94-1.15	
3	Roy2020		30	All-cause death and HF hospitalization	1.00	0.93-1.07	0.95
4	Obokata2016	_	11.4	CV death and HF hospitalization	0.99	0.87-1.13	0.92
5	Gozdzik2021	MAGGIC Risk Score, BNP, and peak VO2	48	CV death and HF hospitalization	0.91	0.84-0.98	0.016
6	Kalra2020	Age, sex, race, medical history (stroke, heart rate, and AF), NYHA class, randomization strata, randomized treatment assignment, hematocrit, and creatinine.	34.8	All-cause death	1.58	1.12-2.22	0.009
7	Kammerlander20 20	Age, sex, NT-pro BNP, LA volume, RV end-diastolic volume, and RV ejection fraction	39	CV death and HF hospitalization	1.06	1.01- 1.11	0.03
8	Romano2020	Age, BMI, medical history (diabetes, hypertension), heart rate, diastolic blood pressure, LV end diastolic volume index, LV ejection fraction, LA volume, and RV ejection fraction	74.4	All case death	1.21	1.157–1.270	< 0.001
9	Hwang2021	-	30	All-cause death and HF hospitalization	1.40	1.176–1.667	< 0.001
10	Donal2017	Age, sex, medical history (arterial hypertension, AF, and renal insufficiency), and hemoglobin.	18	All-cause death and HF hospitalization	1.94	1.22 3.07	0.0047
		Age, sex, medical history (renal insufficiency, diabetes, hypertension,		All case death	1.02	0.96-1.08	0.562
11	Buggey2017	lung disease), systolic blood pressure, NT-pro BNP, RV systolic pressure, moderate mitral stenosis, moderate aortic stenosis, and E/e' ratio.	12	All-cause death and HF hospitalization	1.03	0.98-1.08	0.204
12	Wang2015	Age, sex, medical history (hypertension, diabetes mellitus, and anemia), history of cardiac-related medications, the body surface area, NYHA class	36	All-cause death and HF hospitalization	0.79	0.67-0.91	0.008
13	Huang2017	Sex, race, BMI, echocardiography data, NT-pro BNP, and Troponin T.	37.5	All-cause death	4.72	1.25-17.81	0.022
14	Shah2015	Age, sex, race, medical history (AF, stroke), heart rate, NYHA class, creatinine, echocardiography data (LVEF, LV mass, E/e' ratio.), randomization strata, region of enrollment, randomized treatment assignment	34.8	CV death and HF hospitalization	2.14	1.26-3.66	0.005

Continued Tabel 3. Data related to Meta-analysis of prognostic assessment

NO	Study	Variables adjusted	Follow-up Duration (months)	Endpoint(s)	Hazard ratios	95%CIs	P- value
15	Freed2016	Sex, AF, MAGGIC Risk Score, LV mass, LA volume, E/e' ratio	13.8	All-cause death and CV hospitalization	1.17	0.95-1.43	0.13
		_		All-cause death	1.066	0.964-1.178	0.22
16	Lejeune2020		30	All-cause death and HF hospitalization	1.019	0.951-1.093	0 .59
17	Weerts2021	-	36	All-cause death and HF hospitalization	0.958	0.909-1.010	0.115
		_		HF Hospitalization	1.76	0.23 - 13.52	0.584
18 F	Kosmala2018		26.2	All-cause death and CV hospitalization	2.12	0.35-12.74	0.411

Abbreviations: MAGGIC Risk Score: age, ejection fraction, creatinine, diabetes, chronic obstructive pulmonary disease, systolic blood pressure, body-mass index, heart rate, New York Heart Association functional class, ACE-inhibitor use, beta-blocker use, heart failure duration, and current smoker; AF: atrial fibrillation; NYHA: New York Heart Association; LA: left atrial volume; RV: right ventricular; LV: left ventricular; BMI: body-mass index; LVEF: LV ejection fraction.

Figure Legends

- 663 Fig.1 Flowchart of Database Search and Text Screening Procedure
- 664 Fig.2 Differences in LV GLS Values between HFpEF Patients and Control Groups
- 665 (A) Mean LV GLS Values in HFpEF Patients and Healthy Controls
- 666 (B) Mean LV GLS Values in HFpEF Patients and HFrEF Patients
- 667 (C) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to Healthy Controls
- 668 (D) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to HFrEF Patients
- 669 Fig.3 Diagnostic Value of LVGLS in Patients with HFpEF
- 670 (A) Sensitivity
- 671 (B) Specificity
- 672 (C) Positive Likelihood Ratio
- 673 (D) Negative Likelihood Ratio
- 674 (E) Diagnostic Odds Ratio
- 675 (F) SROC
- 676 Fig.4 Associations between Low LV GLS Values and Adverse Outcomes in HFpEF Patients
- 677 (A) Forest Plot of the Association between Low LV GLS Values and All-cause Death in
- 678 HFpEF Patients
- 679 (B) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome
- of All-cause Death and HF Hospitalization in HFpEF Patients
- 681 (C) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome
- of CV Death and HF Hospitalization in HFpEF Patients





Fig.1 Flowchart of Database Search and Text Screening Procedur




(C) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to Healthy Controls

HFpEF patients			Health	ny contr	ols	:	Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random. 95% CI
Bekfani2021	-18.9	5.5	17	-19.8	3.3	20	4.4%	0.20 [-0.45, 0.85]	-
BlumedRxiv preprint doi: https://do Boscwhich.was not certified by	i.org/10.1101 peer review	/2023.63. v) is the au	13.23 <mark>287</mark> uthor/fund	207; this ve er, who has	rsion poste	d March 1 edRxiv a l	4, 2023. The disp	copyright holder for this preprint lay the preprint in perpetuity.	•
Bshiebish 2019	-15.03	2.03		-19.74	1.12	20	3.5%	2.82 [1.92, 3.71]	
Carluccio2011	-14.4	3.3	47	-20.5	4.9	50	5.1%	1.44 [0.99, 1.89]	-
Carluccio2016	-15.4	3.5	46	-21.5	3.9	40	4.9%	1.64 [1.15, 2.13]	-
Fang 2019	-14.5	2.6	62	-19.6	2.4	50	5.0%	2.02 [1.56, 2.48]	-
Hashemi2021	-19.27	1.25	19	-20.48	1.62	12	4.0%	0.84 [0.08, 1.60]	-
Ito2020	-14.8	3.3	18	-19.5	2.9	18	4.0%	1.48 [0.73, 2.23]	
Kim2020	-15.5	5.3	50	-19.9	2	46	5.1%	1.07 [0.64, 1.50]	-
Kraigher-Krainer2014	-14.6	3.3	219	-20	2.1	50	5.4%	1.73 [1.39, 2.07]	-
Löffler2019	-17.9	3.5	19	-20.5	3.6	15	4.2%	0.72 [0.02, 1.42]	•
Luo2014	-14.02	2.73	58	-17.13	2.07	46	5.1%	1.25 [0.83, 1.68]	-
Mordi2018	-16.05	2.16	62	-19.59	1.49	28	4.8%	1.77 [1.25, 2.29]	
Pellicori2014	-13.6	3	138	-19.1	2.1	20	4.8%	1.88 [1.37, 2.40]	-
Roy2020	-16.5	3.2	143	-21	2.5	31	5.2%	1.45 [1.03, 1.87]	-
Sanchis2015	-16	3.7	63	-17	3.5	43	5.3%	0.27 [-0.12, 0.66]	-
Stoichescu-Hogea2018	-17.6	2.3	62	-20.2	1.4	40	5.1%	1.29 [0.85, 1.73]	-
Tanacli2020	-20.8	4	20	-23.2	3.4	20	4.4%	0.63 [-0.00, 1.27]	-
Wang2008	-13	6	20	-14	5	17	4.4%	0.18 [-0.47, 0.82]	-
Yip2011	-15.9	3.9	112	-20.9	2.5	60	5.4%	1.43 [1.08, 1.78]	-
Total (95% CI)			1431			864	100.0%	1.21 [0.94, 1.47]	•
Heterogeneity: Tau ² = 0.3	0; Chi2 =	134.57	df = 2	0 (P < 0.	00001);	l ² = 85 ⁹	%	-	-
Test for overall effect: Z =					,				-4 -2 0 2 4

(D) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to HFrEF Patients

	HFpEF patients			HFrEF patients		Std. Mean Difference		Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% C	IV. Random, 95% CI
Bekfani2021	-18.9	5.5	17	-6.8	2.9	18	4.5%	-2.71 [-3.66, -1.77]	
Blum2020	-19.1	1.2	17	-11.4	4	18	4.7%	-2.52 [-3.43, -1.60]	
Bosch2017	-14.5	4	219	-7.4	7.3	219	7.7%	-1.20 [-1.41, -1.00]	•
Bshiebish2019	-15.03	2.03	20	-10.72	1.99	20	5.2%	-2.10 [-2.89, -1.31]	-
Carluccio2011	-14.4	3.3	47	-11.6	5.7	40	6.9%	-0.61 [-1.04, -0.18]	•
Hashemi2021	-19.27	1.25	19	-11.51	3.97	18	4.7%	-2.61 [-3.51, -1.71]	-
Luo2014	-14.02	2.73	58	-8.28	2.67	45	6.7%	-2.11 [-2.59, -1.62]	•
Maffeis2022	-19	3	58	-7	2	86	5.8%	-4.87 [-5.53, -4.21]	•
Michalski2017	-16.12	6.4	32	-10.68	2.99	30	6.4%	-1.06 [-1.60, -0.53]	*
Obokata2016	-14.3	2.8	102	-8.4	2.7	340	7.5%	-2.16 [-2.43, -1.90]	•
Park2018	-15.2	4.6	1335	-8.1	3.3	2195	7.9%	-1.85 [-1.93, -1.77]	•
Sanchis2015	-16	3.7	63	-9.5	4.5	32	6.7%	-1.62 [-2.10, -1.13]	*
Tanacli2019	-20	3.3	18	-11	3.2	20	4.7%	-2.71 [-3.62, -1.81]	-
Wang2008	-13	6	20	-5	2	30	5.7%	-1.93 [-2.62, -1.24]	*
Xu2021	-18	3.3	97	-11.9	2.8	69	7.1%	-1.96 [-2.33, -1.58]	
Yip2011	-15.9	3.9	112	-9.6	3.6	175	7.5%	-1.69 [-1.96, -1.41]	•
Total (95% CI)			2234			3355	100.0%	-2.03 [-2.33, -1.72]	♦
Heterogeneity: Tau ² =	0.31; Chi	² = 178	.01, df	= 15 (P <	0.000	01); I ² =	92%		
Test for overall effect:				-					-10 -5 0 5 10

Fig.2 Differences in LV GLS Values between HFpEF Patients and



Positive LR (95% CI)

2.23 (1.35 - 3.69)

1.51 (1.09 - 2.08)

1.50 (1.02 - 2.21)

3.55 (1.71 - 7.35)

16.15 (2.41 - 108.42)

Mordi2018

Tanacli2020

Kim2020

Wang2008

Stoichescu-Hogea2018

(D) Negative Likelihood Ratio

Negative LR (95% CI) 0.28 (0.15 - 0.51)

(0.25 - 0.79)

(0.06 - 1.03)

0.54 (0.39 - 0.75)

0.05 (0.01 - 0.36)

0.44

0.25

Mordi2018

Tanacli2020

Kim2020

Wang2008

Stoichescu-Hogea2018

(C) Positive Likelihood Ratio





Fig.3 Diagnostic Value of LVGLS in Patients with HFpEF



(B) Forest Plot of the Association between	en Low LV GLS Values and the Con	nposite Outcome of All-cause	Death and	HF Hospitalization in F	IFpEF Patients
Study		Patients	Events	HR (95% CI)	Weight(%)
Roy2020		143	87	1.00 (0.93, 1.07)	18.08
Hwang2021		1105	574	1.40 (1.18, 1.67)	10.52
Donal2017	-	237	_	1.94 (1.22, 3.07)	2.61
Buggey2017	•	739	134	1.03 (0.98, 1.08)	19.49
Wang2015	—	80	43	0.79 (0.67, 0.91)	11.84
Lejeune2020	*	149	91	1.02 (0.95, 1.09)	18.17
Weerts2021	→	258	66	0.96 (0.91, 1.01)	19.28
Overall, DL (I ² = 83.1%, p = 0.000)	\Diamond			1.03 (0.95, 1.11)	100.00
.5	1	5			

Study	Patients	Events	HR (95% CI)	Weight(%)
Pellicori2014	138	62	1.09 (1.00, 1.19)	24.21
Obokata2016	102	35	0.99 (0.87, 1.13)	19.60
Gozdzik2021 —	201	74	0.91 (0.84, 0.98)	25.22
Kammerlander2020	206	109	1.06 (1.01, 1.11)	27.88
Shah2015 — *	447	115	2.14 (1.26, 3.66)	3.09
Overall, DL (I ² = 80.5%, p = 0.000)			1.04 (0.94, 1.14)	100.00
.5 1 5	 5			

(C) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome of CV Death and HF Hospitalization in HFpEF Patients

Fig.4 Associations between Low LV GLS Values and Adverse Outo